Shares of Health Care sector company Biogen moved -2.8% today, and are now trading at a price of $230.06. The Large-Cap stock's daily volume was 1,464,056 compared to its average volume of 1,115,254. The S&P 500 index returned a 1.0% performance.
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company is based in Cambridge and has 7,570 full time employees. Its market capitalization is $33,496,043,520.
29 analysts are following Biogen and have set target prices ranging from $200.0 to $350.0 per share. On average, they have given the company a rating of buy. At today's prices, BIIB is trading -17.95% away from its average analyst target price of $280.4 per share.
Over the last year, BIIB shares have gone down by -17.4%, which represents a difference of -41.5% when compared to the S&P 500. The stock's 52 week high is $281.12 per share and its 52 week low is $189.44. Although Biogen's average free cash flow over the last 5 years has been $3.6 Billion, they have been decreasing at an average rate of -26.7%. For this reason, investors may continue to shun the stock.
| Date Reported | Cash Flow from Operations ($ k) | Capital expenditures ($ k) | Free Cash Flow ($ k) | YoY Growth (%) |
|---|---|---|---|---|
| 2023 | 1,547,200 | 277,000 | 1,270,200 | 11.03 |
| 2022 | 1,384,300 | 240,300 | 1,144,000 | -66.17 |
| 2021 | 3,639,900 | 258,100 | 3,381,800 | -11.12 |
| 2020 | 4,229,800 | 424,800 | 3,805,000 | -42.03 |
| 2019 | 7,078,600 | 514,500 | 6,564,100 | 21.17 |
| 2018 | 6,187,700 | 770,600 | 5,417,100 |
